Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Trial Profile

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Vemurafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.
    • 02 May 2017 Status changed from recruiting to discontinued because second cohort not opened because Simon-Two_Step model failed
    • 07 Jun 2016 Results from phase IIa portion of the study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top